Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016

Archive ouverte

Orbai, Ana-Maria | de Wit, Maarten | Mease, Philip J. | Callis Duffin, Kristina | Elmamoun, Musaab | Tillett, William | Campbell, Willemina | Fitzgerald, Oliver | Gladman, Dafna D. | Goel, Niti | Gossec, Laure | Hoejgaard, Pil | Leung, Ying Ying | Lindsay, Chris | Strand, Vibeke | Heijde, Désirée M., van Der | Shea, Bev | Christensen, Robin | Coates, Laura | Eder, Lihi | Mchugh, Neil | Kalyoncu, Umut | Steinkoenig, Ingrid | Ogdie, Alexis

Edité par CCSD -

International audience. Objective. To include the patient perspective in accordance with the Outcome Measures in Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials (RCT) and longitudinal observational studies (LOS). Methods. At OMERACT 2016, research conducted to update the PsA Core Domain Set was presented and discussed in breakout groups. The updated PsA Core Domain Set was voted on and endorsed by OMERACT participants. Results. We conducted a systematic literature review of domains measured in PsA RCT and LOS, and identified 24 domains. We conducted 24 focus groups with 130 patients from 7 countries representing 5 continents to identify patient domains. We achieved consensus through 2 rounds of separate surveys with 50 patients and 75 physicians, and a nominal group technique meeting with 12 patients and 12 physicians. We conducted a workshop and breakout groups at OMERACT 2016 in which findings were presented and discussed. The updated PsA Core Domain Set endorsed with 90% agreement by OMERACT 2016 participants included musculoskeletal disease activity, skin disease activity, fatigue, pain, patient's global assessment, physical function, health-related quality of life, and systemic inflammation, which were recommended for all RCT and LOS. These were important, but not required in all RCT and LOS: economic cost, emotional well-being, participation, and structural damage. Independence, sleep, stiffness, and treatment burden were on the research agenda. Conclusion. The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of PsA outcome measures and development of a PsA Core Outcome Measurement Set.

Suggestions

Du même auteur

International Patient and Physician Consensus on a Psoriatic Arthritis Core Outcome Set for Clinical Trials

Archive ouverte | Orbai, Ana-Maria | CCSD

International audience. OBJECTIVE: To identify a core set of domains (outcomes) to be measured in psoriatic arthritis (PsA) clinical trials that represent both patients' and physicians' priorities. METHODS: We condu...

Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group

Archive ouverte | Leung, Ying-Ying | CCSD

International audience. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)–Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group—comprising rheumatologis...

A Systematic Review of Measurement Properties of Patient Reported Outcome Measures in Psoriatic Arthritis: A GRAPPA-OMERACT Initiative

Archive ouverte | Højgaard, Pil | CCSD

International audience. Background: An updated psoriatic arthritis (PsA) core outcome set (COS) for randomized controlled trials (RCTs) was endorsed at the Outcome Measures in Rheumatology (OMERACT) meeting in 2016....

Chargement des enrichissements...